Related by context. All words. (Click for frequent words.) 80 virological failure 77 virologic response 75 sustained virologic response 74 virological response 74 severe neutropenia 73 APTIVUS r 73 ribavirin therapy 72 HBeAg seroconversion 72 seroconversion 72 NNRTI resistance 72 undetectable HCV RNA 72 antiretroviral naive 72 definite stent thrombosis 72 genotypic resistance 72 peginterferon 72 PREZISTA r 72 undetectable viral load 71 recurrent VTE 71 ribavirin RBV 71 nelfinavir 71 HAART regimen 70 LEXIVA r 70 NRTI 70 mg kg dose 70 ALT flares 70 lamivudine 70 chlorambucil 70 CCyR 70 sustained virological response 69 tamoxifen therapy 69 viral suppression 69 HIV RNA 69 TEAEs 69 TDF FTC 69 receiving VICTRELIS 69 SVR# 69 adefovir 69 raltegravir 69 insulin detemir 69 lopinavir r arm 69 β blockers 69 fosamprenavir 69 biochemical relapse 69 virologic failures 69 atazanavir ritonavir 69 peginterferon alfa 2a 69 NNRTI 69 virologic breakthrough 69 vicriviroc 69 NNRTIs 68 evaluable subjects 68 relapsed MM 68 nonresponders 68 CR nPR 68 posaconazole 68 decitabine 68 protease inhibitor PI 68 CD4 + cell 68 LPV r 68 dosage regimens 68 virologic 68 HCV genotype 68 tipranavir r 68 baseline HbA1c 68 HBeAg positive patients 68 HBeAg negative patients 68 mg/m2 dose 68 thromboembolic events 68 BARACLUDE ® 68 Pegasys plus Copegus 68 detectable HCV RNA 68 mg BID 68 tipranavir 68 hematologic toxicity 68 adalimumab 68 mycophenolate mofetil 68 ABC/3TC 68 rFVIIa 68 virologically 68 mRCC 68 5-FU/LV 68 virologic responses 68 antiretroviral naïve 68 amoxicillin clavulanate 68 mcg BID 68 peginterferon alfa 2b 68 ISENTRESS 68 tirofiban 68 platelet reactivity 68 eplerenone 68 pCR 68 abacavir lamivudine 68 rapid virologic response 68 cART 67 ritonavir boosted 67 interferon ribavirin 67 complete cytogenetic response 67 ritonavir boosted lopinavir 67 lopinavir 67 AZT zidovudine Retrovir 67 CANCIDAS 67 virologic suppression 67 darunavir ritonavir 67 hepatitis C genotype 67 fluvastatin 67 heavily pretreated 67 flutamide 67 d4T 67 seroprotection 67 cabazitaxel 67 Elitek 67 ipsilateral stroke 67 NRTIs 67 zidovudine 67 pyrazinamide 67 BENICAR HCT 67 HbA 1c levels 67 doxorubicin docetaxel 67 PegIFN RBV 67 #mg QD [001] 67 valacyclovir 67 FOLFOX4 67 viremia 67 progression TTP 67 HBeAg positive 67 HbA1c levels 67 HBV DNA 67 atazanavir 67 undetectable HBV DNA 67 Kaplan Meier analysis 67 achieved ACR# 67 INTELENCE 67 lopinavir r 67 tipranavir ritonavir 67 timepoint 67 PASI scores 67 experienced virologic failure 67 #mg/m# [001] 67 nadolol 67 peg IFN 66 DMARD 66 HBV DNA levels 66 periprocedural 66 REYATAZ r arm 66 tenofovir emtricitabine 66 antibody titer 66 K#N 66 invasive aspergillosis 66 TMP SMX 66 comparator arm 66 paricalcitol 66 cytogenetic response 66 disease progression 66 enfuvirtide 66 HCV genotype 1 66 androgen deprivation 66 serum creatinine levels 66 antiretroviral regimens 66 rilpivirine 66 #mg BID [001] 66 HAART 66 darunavir 66 ertapenem 66 mcg dose 66 DAPT 66 Peg IFN 66 anemia hemoglobin 66 log# reduction 66 pegylated interferon alfa 2b 66 prospectively defined 66 peginterferon alfa 66 reinfarction 66 β blocker 66 transaminase elevations 66 oxycodone CR 66 octreotide LAR 66 dasatinib 66 pegylated interferon 66 mg QD 66 HBeAg negative 66 lipid lowering drugs 66 viral load 66 FOLFIRI 66 docetaxel chemotherapy 66 beta blocker therapy 66 trastuzumab Herceptin ® 66 trimethoprim sulfamethoxazole 66 entecavir 66 hemorrhagic complications 66 HBeAg 66 serum HCV RNA 66 pegylated interferon alfa 66 rizatriptan 66 biochemical recurrence 66 PREZISTA rtv 66 infliximab 66 Doxil ® 66 mitoxantrone 66 FOLFOX 66 TMC# r 66 divalproex sodium 66 imipenem 66 neoadjuvant 66 elotuzumab 66 null responders 66 CD4 cell 66 Hb A1C 66 anthracycline containing 66 lipid lowering therapy 66 clodronate 66 Telintra 66 PEG IFN 66 annualized relapse 65 nilotinib 65 EGFR TKI 65 pegylated interferon alpha 65 #mg QD [002] 65 % CI #.#-#.# [003] 65 adenoma recurrence 65 dosing cohorts 65 HAART regimens 65 peg interferon 65 bisphosphonate therapy 65 aminotransferase elevations greater 65 seroconverted 65 gout flares 65 saline placebo 65 placebo dexamethasone 65 ddI 65 indinavir 65 plus dexamethasone 65 adriamycin 65 FOLPI 65 seropositive patients 65 HCV RESPOND 2 65 spontaneous preterm birth 65 elevated ALT 65 COMBIVIR 65 unfractionated heparin 65 NATRECOR R 65 metastatic RCC 65 coinfected 65 imatinib 65 azacitidine 65 trastuzumab 65 VIRAMUNE 65 tolvaptan 65 3TC lamivudine Epivir 65 FluCAM 65 pomalidomide 65 vandetanib 65 dacarbazine 65 XIENCE V PROMUS Stent 65 CsA 65 noninferiority 65 nitazoxanide 65 postoperative chemotherapy 65 HCV RNA 65 ATACAND 65 NATRECOR ® 65 prior chemotherapy regimens 65 GnRH agonist 65 eptifibatide 65 endometrial carcinoma 65 CMV disease 65 VELCADE melphalan 65 antihypertensive therapy 65 timepoints 65 MCyR 65 complete cytogenetic 65 thromboembolism 65 binary restenosis 65 viral loads 65 efavirenz EFV 65 plasma uric acid 65 dexamethasone Decadron 65 antiandrogen 65 concomitant medications 65 candidemia 65 piperacillin tazobactam 65 anagrelide 65 prolonged QT interval 65 idarubicin 65 dalteparin 65 postintervention 65 QTc prolongation 65 antiviral efficacy 65 daunorubicin 65 COPEGUS 65 morphometric vertebral fractures 65 advanced adenoma 65 AGILECT R 65 abacavir 64 severe exacerbations 64 copies mL 64 antiviral therapy 64 q#h 64 DLTs 64 non squamous NSCLC 64 DOXIL 64 asthma exacerbation 64 metastatic CRC 64 desvenlafaxine succinate 64 serum urate 64 lumbar spine BMD 64 NAbs 64 CMV infection 64 RLAI 64 steroid dexamethasone 64 benazepril 64 abatacept 64 liver transplant recipients 64 stavudine 64 androgen suppression 64 adjuvant tamoxifen 64 noninferior 64 certolizumab 64 intensive statin therapy 64 sunitinib 64 recurrent glioblastoma multiforme 64 serum HBV DNA 64 boosted protease inhibitor 64 corticosteroid therapy 64 methotrexate monotherapy 64 RRMS patients 64 colorectal adenoma 64 remission CR 64 copies ml 64 adefovir treated 64 PSADT 64 mg ustekinumab 64 PSA nadir 64 rFSH 64 anthracycline taxane 64 undetectable viral loads 64 active comparator 64 carboplatin paclitaxel 64 glycated hemoglobin levels 64 nevirapine Viramune 64 telbivudine 64 -#.# log# 64 alfa 2a 64 achieved sustained virological 64 bosentan 64 interferon alfa 64 evaluable 64 CIMZIA TM 64 dose regimens 64 EXJADE 64 antiplatelet therapy 64 serum phosphorous 64 alteplase 64 p = NS 64 IELT 64 undetectable viral 64 median PFS 64 lispro 64 olmesartan 64 XELOX 64 PREZISTA r arm 64 Pegylated Liposomal Doxorubicin 64 tamsulosin 64 R# #mg BID 64 azathioprine 64 zidovudine lamivudine 64 NPH insulin 64 febrile neutropenia 64 blastic phase 64 OGTT 64 mcg QD 64 bendamustine 64 neoadjuvant chemotherapy 64 tapentadol ER 64 alanine aminotransferase 64 recurrent genital herpes 64 FDA defined valvulopathy 64 dose cohort 64 concomitant antibiotics 64 neutrophil counts 64 hepatotoxicity 64 fibrinolysis 64 acromegalic patients 64 plasma HCV RNA 64 sUA 64 stage IIIB 64 stavudine d4T 64 A1c levels 64 idraparinux 64 BYSTOLIC 64 #mg dose [002] 64 viral kinetics 64 ARB telmisartan 64 PegIntron 64 potent antiretroviral therapy 64 cilostazol 64 K ras mutations 64 chronic HCV infection 64 low dose cytarabine 64 exemestane 64 interferon therapy 64 HSCT 64 ibandronate 64 virologically suppressed 64 endometrial hyperplasia 64 ritonavir boosted atazanavir 64 oral vancomycin 64 nonadherence 64 serum testosterone 64 Reverset 64 pegylated liposomal doxorubicin 64 bezafibrate 64 intravenous bisphosphonates 64 cerebrovascular events 64 pentoxifylline 64 weekly subcutaneous injections 64 mcg albinterferon alfa 2b 63 nonfatal MI 63 Flu Cy 63 thrombotic events 63 mCRC patients 63 serum urate levels 63 thrombocytopenic 63 nucleoside analogues 63 solifenacin 63 COPD exacerbation 63 telaprevir dosed 63 #mg BID [003] 63 Dasatinib 63 laboratory abnormalities 63 antimicrobial prophylaxis 63 Subgroup analyzes 63 mg RDEA# 63 linezolid 63 metastatic renal cell carcinoma 63 #mg/day [001] 63 infusional 5-FU/LV 63 dose cohorts 63 canakinumab 63 thromboembolic complications 63 aspartate aminotransferase AST 63 Fludara 63 dose dexamethasone 63 imatinib therapy 63 antihypertensive medications 63 symptomatic VTE 63 irbesartan 63 HCV infected 63 nonnucleoside reverse transcriptase inhibitors 63 NRTI backbone 63 tumor recurrence 63 TORISEL 63 ACR# response 63 MULTAQ 63 plus gemcitabine 63 nondiabetic patients 63 ALT normalization 63 fluticasone salmeterol 63 receiving prophylactic anticoagulation 63 dosing cohort 63 virologic response EVR 63 alanine aminotransferase ALT 63 mcg kg 63 caspofungin 63 acute gout flares 63 paroxysmal AF 63 APTIVUS 63 biologic DMARD 63 HCV SPRINT 63 IFN beta 63 μmol L 63 Stent thrombosis 63 co trimoxazole 63 renal toxicity 63 hypokalemia 63 antiretroviral regimen 63 LVEF 63 seropositivity 63 intravenous dosing 63 quetiapine 63 GnRH agonists 63 prespecified 63 Virologic 63 undetectable virus HCV 63 heavily pretreated patients 63 PREZISTA ritonavir 63 ACTEMRA TM 63 antibody titers 63 urate lowering therapy 63 pegylated liposomal doxorubicin PLD 63 highly emetogenic 63 serum phosphate 63 limiting toxicity 63 tigecycline 63 chlamydial infection 63 corrected QT interval 63 composite endpoint 63 baseline CD4 63 VICTRELIS 63 recurrent venous thromboembolism 63 gefitinib 63 mcg Albuferon 63 Cmax 63 HBsAg 63 FOLFOX6 63 DMARD therapy 63 hypophosphatemia 63 serum phosphorus 63 APTIVUS ritonavir 63 voriconazole 63 monotherapy 63 adjunctive placebo 63 cytopenias 63 fondaparinux 63 CIMZIA ™ 63 dapagliflozin plus 63 Pegasys ® 63 lamotrigine 63 prospectively stratified 63 arterial thromboembolic events 63 VFEND 63 pegylated interferon alfa 2a 63 stable angina 63 lamivudine refractory patients 63 aldosterone antagonist 63 etravirine 63 8mg/kg 63 postprocedure 63 MADRS score 63 administered subcutaneously 63 genotype 1b 63 poor metabolizers 63 protease inhibitors PIs 63 Torisel 63 dose cytarabine 63 Folfox 63 serum IGF 63 nadroparin 63 prednisone prednisolone 63 #mg/m# [002] 63 temsirolimus 63 curative resection 63 moderate renal impairment 63 oral olanzapine 63 receiving ISENTRESS 63 4mg/kg 63 CCR5 tropic HIV 63 LV dysfunction 63 gout flare 63 topotecan 63 nicardipine 63 cEVR 63 HCV genotypes 63 clomipramine 63 splenectomized patients 63 Non inferiority 63 QTcF 63 nab paclitaxel 63 KRAS mutant tumors 63 hemoglobin A1c levels 62 pegIFN 62 dose titration 62 creatinine clearance 62 vertebral fracture 62 lopinavir ritonavir Kaletra 62 tenecteplase 62 mg dose 62 Viral load 62 vaccinees 62 severe hypersensitivity reactions 62 HbA 1c 62 leukopenia 62 nonvertebral fractures 62 log# copies mL 62 placebo 62 neurologic progression 62 statistical significance p 62 Free Survival PFS 62 darunavir r 62 antiretroviral therapy ART 62 EDSS score 62 discontinuations due 62 response CCyR 62 spontaneous preterm delivery 62 ethambutol 62 tocilizumab 62 advanced adenomas 62 bolus dose 62 relapsers 62 d4T stavudine Zerit 62 riociguat 62 thromboembolic 62 anastrozole 62 Aptivus ® 62 endophthalmitis 62 oblimersen 62 antibiotic prophylaxis 62 TMC# [001] 62 QTc 62 PEG Interferon alfa 62 Postoperative complications 62 TNF antagonist 62 % CI #.#-#.# [007] 62 Virologic failure 62 COPD exacerbations 62 SCIg 62 antiretroviral therapy 62 chemoradiotherapy 62 NSTE ACS 62 argatroban 62 antihypertensive drugs 62 hypoglycemic episodes 62 lymphocyte counts 62 cytotoxic therapy 62 μg dose 62 tiotropium 62 levetiracetam 62 q#d 62 Kaplan Meier estimates 62 #mg q8h 62 SCr 62 oral rivaroxaban 62 Pegylated Interferon 62 telaprevir dosing 62 renal impairment 62 dose escalation phase 62 CrCl 62 serum potassium 62 serum aminotransferase levels 62 ancrod 62 T2DM 62 warfarin therapy 62 recurrent UTI 62 relapsing MS 62 pneumonectomy 62 NRTI resistance 62 LMWH 62 unfractionated heparin UFH 62 mcg mL 62 BEACOPP 62 multivariate Cox 62 Sprycel dasatinib 62 Index CDAI 62 CCR5 antagonist 62 preintervention 62 nonnucleoside reverse transcriptase inhibitor 62 Sustained Virological Response 62 tolterodine 62 STRIDE PD 62 Xelox 62 mL/min/#.# m 2 62 elevated LDL cholesterol 62 ELOXATIN 62 relapsed ovarian cancer 62 diuretic chlorthalidone 62 Taxotere ® 62 CHOP chemotherapy 62 creatinine levels 62 conventional antipsychotics 62 invasive candidiasis 62 enalapril 62 aldosterone antagonists 62 ULORIC 62 gemcitabine carboplatin 62 HIV uninfected 62 Dose escalation 62 preoperative chemotherapy 62 anemia neutropenia 62 hypercalcemia 62 zidovudine AZT 62 HPV-#/# 62 leukemia AML 62 combination antiretroviral therapy 62 methotrexate therapy 62 RESIST studies 62 carotid IMT 62 discontinuations 62 severe hypoglycemic 62 aprepitant 62 antithrombotic therapy 62 median CD4 62 TNF inhibitor 62 elevated transaminases 62 hypoglycemic events 62 renal flares 62 renal dysfunction 62 aminotransferases 62 reperfusion therapy 62 MACCE 62 YERVOY 62 Engerix B 62 AST ALT 62 INFERGEN 62 posttreatment 62 lymphocyte count 62 iniparib 62 acute GvHD 62 peginterferon alpha 2a 62 plus ribavirin 62 oral allopurinol 62 P = .# 62 sulfadoxine pyrimethamine 62 pulmonary exacerbation 62 chronic HCV 62 levosimendan 62 locoregional 62 serum uric acid 62 ICD implantation 62 infliximab therapy 62 refractory CLL 62 ng dL 62 EBRT 62 achieved CCyR 62 latent tuberculosis infection 62 rHuEPO 62 reach statistical significance 62 oral anticoagulation 62 achieved sustained virologic 62 IFN α 62 antidiabetic medication 62 atazanavir sulfate 62 rimonabant #mg 62 doxorubicin cyclophosphamide 62 symptom exacerbation 62 interferon alfa 2a 62 ascending doses 62 Sustained virologic response 62 q8h 62 NRTI sparing 62 tumor lysis syndrome 62 hsCRP levels 62 lenalidomide Revlimid R 62 efalizumab 62 cangrelor 62 clopidogrel Plavix 62 secondary efficacy endpoints 62 ARCOXIA 62 amisulpride 62 HIV HCV coinfected 62 univariate analysis 62 palivizumab 62 serum concentrations 62 Subgroup analysis 62 cytoreduction 62 HBV infection 62 coronary revascularization 62 peginterferon alfa 2a #KD 62 docetaxel 62 mg TID 62 Viread Emtriva 62 baminercept 62 ximelagatran 62 severe hypoglycemia 62 isoniazid 62 nephrotoxicity 62 oral prednisone 62 TYKERB 62 ziprasidone 62 adjuvant therapy 62 dose regimen 62 REYATAZ 61 TT genotype 61 lymphopenia 61 HER2 expression 61 colorectal liver metastases 61 bortezomib 61 AZT 3TC 61 receiving INTRON 61 undetectable hepatitis C 61 REYATAZ r 61 troponin T 61 Telbivudine 61 evaluable patients 61 treatment naive genotype 61 pulmonary exacerbations 61 EDSS scores 61 patients evaluable 61 serum potassium levels 61 sulfasalazine 61 inhibitor RG# 61 serum calcium levels 61 rhGH 61 intravenous diuretics 61 randomisation 61 aspartate aminotransferase 61 goserelin 61 pegylated interferon peg IFN 61 coadministration 61 subclinical hypothyroidism 61 #mg/day [002] 61 REYATAZ ritonavir 61 MS relapses 61 IU mL 61 venous thromboembolic events 61 DAS# remission 61 ritonavir boosted protease inhibitor 61 virological suppression 61 fluconazole 61 microalbuminuria 61 refractory NSCLC 61 lymphocytosis 61 TPV r 61 nucleoside naive 61 Epivir 61 fluorouracil 61 baseline LDH 61 HER2 overexpression 61 elvitegravir 61 Thrombocytopenia 61 CRp 61 CR CRu 61 % CI #.#-#.# [006] 61 abacavir Ziagen 61 events SAEs 61 eosinophilic asthma 61 serum estradiol 61 IV NSCLC 61 sitagliptin 61 endoscopic remission 61 QTc interval 61 R0 resection 61 VT VF 61 mg qd 61 anti HBs 61 mutated KRAS 61 SHBG levels 61 INVEGA ® 61 amprenavir 61 Febrile neutropenia 61 paroxetine Paxil 61 chronic GVHD 61 complete remissions 61 events AEs 61 chlorthalidone 61 sorafenib Nexavar 61 tumor histology 61 thromboprophylaxis 61 PegIFN 61 CC genotype 61 doripenem 61 BARACLUDE 61 valvulopathy 61 ZYVOX 61 OADs 61 nonvertebral fracture 61 perioperative mortality 61 salmeterol fluticasone 61 grade cervical intraepithelial 61 antidepressant therapy 61 moderately emetogenic 61 intermittent dosing 61 postoperative AF 61 advanced neoplasia 61 PRADAXA #mg 61 randomized #:#:# 61 PROMACTA 61 cidofovir 61 valsartan 61 systolic dysfunction 61 leukemia ALL 61 MMSE score 61 plus MTX 61 SPRYCEL ® 61 postoperative mortality 61 Capecitabine 61 Aggrenox R 61 rt PA 61 platelet inhibition 61 mg/m2/day 61 interquartile range 61 GSK# [001] 61 Peginterferon Alfa 2a 61 antithrombotics 61 aPTT 61 clopidogrel 61 CIMZIA TM certolizumab pegol 61 clinically meaningful improvement 61 postmenopausal osteoporotic women 61 Thal Dex 61 teriflunomide 61 AVODART 61 locoregional recurrence 61 nucleoside naive patients 61 PROSTVAC VF 61 stage IIIb IV 61 zotarolimus eluting stent 61 IIIa inhibitors 61 lopinavir ritonavir 61 myelosuppression 61 coinfected patients 61 liver histology 61 nephrotoxic drugs 61 macroalbuminuria 61 apremilast 61 comparator PI r 61 left ventricular dysfunction 61 interferon alfa 2b 61 recurrent atrial fibrillation 61 hydroxymethyl coenzyme 61 CD4 counts 61 neoadjuvant treatment 61 angiotensin converting enzyme inhibitors 61 docetaxel prednisone 61 cobicistat 61 relapsed AML 61 Bezielle 61 montelukast 61 dexamethasone 61 serum phosphate levels 61 trials RCTs 61 pioglitazone 61 postoperative complication 61 TAXUS Stent 61 symptomatic hypotension 61 protease inhibitor 61 endometrial thickness 61 valopicitabine 61 titrated glipizide 61 mcg doses 61 histologically confirmed 61 polyp recurrence 61 oral FTY# 61 salmeterol HFA MDI 61 prostate cancer CaP 61 galiximab 61 lipid lowering medications 61 Femara letrozole 61 p = #.# [003] 61 tranylcypromine 61 mg eq 61 carvedilol 61 aromatase inhibitor therapy 61 systemic corticosteroids 61 amphotericin B 61 UGT#A# * 61 #mg dose [003] 61 efficacy endpoint 61 REVLIMID ® 61 #mg dose [001] 61 typical antipsychotics 61 pegylated interferons 61 bolus injection 61 NYHA functional class 61 achieved statistical significance 61 postexposure prophylaxis 61 lipid lowering therapies 61 iclaprim 61 subtrochanteric 61 HIV seroconversion 61 abnormal Pap test 61 Median survival 61 ribavirin 61 zolmitriptan 61 triple nucleoside 61 metastatic malignant melanoma 61 receiving golimumab 61 hypomagnesemia 61 hyperbilirubinemia 61 plasma folate 61 graft occlusion 61 Viread Emtriva Sustiva 61 cediranib 61 5-fluorouracil/leucovorin 61 dosing regimens 61 adjuvant radiation 61 insulin glargine 61 proteinuria 61 taxane chemotherapy 61 fibrinolytic 61 posttransplant 61 NYHA class 61 lamivudine monotherapy 61 candesartan 61 daily subcutaneous injections 61 mg Proellex 61 Pred Forte 61 recurrent ischemia 61 visilizumab 61 Serious adverse reactions 61 mg d 61 confidence interval #.#-#.# 61 TAXOTERE R 61 lenalidomide dexamethasone 61 variceal bleeding 61 SPRYCEL 61 paclitaxel eluting stents 61 #mg BID [002] 61 SCCHN 61 intracranial hemorrhage ICH 61 ceftriaxone 61 antihypertensive agents 61 immunosuppressive agents 61 intraocular inflammation 60 micafungin 60 STELARA ® 60 achieve sustained virologic 60 ARIXTRA 60 PEGINTRON TM 60 ALT elevations 60 IIIa inhibitor